Division of Hematology, Montefiore Medical Center of the Albert Einstein College of Medicine, New York, USA
Publications
-
Research Article
Safety of Direct Acting Oral Anticoagulants (DOACs) in Comparison to Enoxaparin in Gastrointestinal and Genito-Urinary Cancers
Author(s): Shafia Rahman, Juan Trias*, Mohammad Barouqa*, Margarita Kushnir and Henny H. Billettc
Abstract
Safety of Direct Oral Anticoagulants (DOAC) in Cancer Associated Thrombosis
(CAT) in patients with Gastrointestinal (GI) and Genito-Urinary (GU) malignancies
is uncertain. We identified patients with active GI and GU malignancies who
received either enoxaparin or a DOAC (apixaban or rivaroxaban) for CAT from
July 2001 to July 2020. Demographics, disease characteristics, thrombosis data,
date of anticoagulation initiation, and bleeding events at one year were recorded
and analysed. We identified 206 patients, 159 received DOAC (86 apixaban;
73 rivaroxaban) and 47 enoxaparin; 128 (62.1%) and 78 (37.9%) had GI and
GU malignancies, respectively. Choice of anticoagulation varied significantly
based on primary malignancy. Enoxaparin was preferred in GU tumors while
DOACs were preferred in GI tumors (p=0.014). Within DOACs, rivaroxaban use
was higher with GI ..
Read More»
